Join our daily newsletter At The Bell to receive exclusive market insights
- AnteoTech (ADO) signs a distribution agreement with UC Biosciences for its EuGeni Reader platform and its COVID-19 test in the Philippines
- The three-year agreement gives UC Biosciences exclusive sales rights in the Philippines
- The parties will jointly review and respond to public and private tender opportunities
- On the market, AnteoTech is up 13.5 per cent and is trading at 21 cents per share
AnteoTech (ADO) has signed a distribution agreement with UC Biosciences for its EuGeni Reader platform and its COVID-19 test in the Philippines.
UC Bioscience is headquartered in Singapore and has offices in Malaysia, Myanmar and Philippines.
The three-year agreement gives UC Biosciences exclusive sales rights in the Philippines.
The parties will jointly review and respond to public and private tender opportunities.
AnteoTech CEO Derek Thomson is pleased to welcome UC Biosciences as a distribution partner.
“[UC Biosciences] has over 40 years’ experience as a distributor, with a strong sales network. The Philippines has a population of over 100 million people and have used rapid antigen testing as a tool within their pandemic response.,” he said.
“With [UC Biosciences] coming on board, we have expanded our distribution network and coverage across South East Asia. Over the coming weeks we will work with [UC Biosciences] to ensure we have the required regulatory approvals in place to commence selling into the Philippines market.”
In July, the company signed a distribution agreement with Abacus for its products in Australia, New Zealand and Pacific Islands.
On the market, AnteoTech is up 13.5 per cent and is trading at 21 cents per share at 11:42 am AEST.
